ADCT股价有吸引力

ADCT is one of the top Antibody-Drug Conjugate (ADC) contenders on the market with a large pipeline and an already approved ADC (Zynlonta), which is now selling in the US and approved in Europe. Europe sales begin in 2Q23. (about 2 weeks from now)

Recent big name buyouts in the ADC space were:

1.) Gilead bought Immunomedics - $20Billion

2.) Pfizer bought Seagen - $43Billion

Merck got beat out by Pfizer when they bought Seagen just recently.

I'm sure Merck is still on the hunt for another top ADC company with a rich pipeline like ADCT.

Hope we are on the radar for the next Buyout!